Sign inJoin waitlistJoin the waitlist

Nilanjan Ghosh

Co-Leader · Wake Forest University Baptist Medical Center

Credentials: · · · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

Johns Hopkins University School of Medicine
2008–2010
Hematology and Medical Oncology
Johns Hopkins University School of Medicine
2005–2008
University of South Florida
Internal Medicine
Long Island Jewish Medical Center - Northwell Health
2002–2005
University of South Florida
USF Health Morsani College of Medicine
1998–2002
University of Mumbai
1994–1997
University of South Florida
1989–1993

Research

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · 2,058 citations
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
New England Journal of Medicine · 2018 · 972 citations
Development of effective quantum mechanical/molecular mechanical (QM/MM) methods for complex biological processes
The Journal of Physical Chemistry B · 2006 · 228 citations

TF
Timothy Fenske
18 papers
Edward Copelan
17 papers
Jonathon Cohen
17 papers
Belinda Copelan
15 papers
Brian Hill
15 papers
Mohamed Dabaja
15 papers
Narendranath Epperla
13 papers
Natalie Grover
13 papers
Ryan Jacobs
13 papers · 1 as a fellow
Steven Park
13 papers
Michael Grunwald
12 papers
Sairah Ahmed
12 papers

Clinical trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Principal investigator · Terminated · Phase 1
Hutchmed
2019–2024
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
Principal investigator · Terminated · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012–2014
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2030